Jiha Lee is a Rheumatology/Immunology physician affiliated with University of Michigan. OpenAlex indexes 41 publications with 554 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.9%Folate Analog Metabolic Inhibitor21.4%Methotrexate100%Part D≥30 patientsTNF inhibitor18%Humira(Cf) Pen44%Cimzia (2 Pack)15%Humira Pen15%Enbrel Sureclick15%Enbrel12%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
14.1%Corticosteroid11.3%Prednisone100%Part D≥16 patientsProton pump inhibitor2.8%Omeprazole100%Part D<11 patientsAntiparasitic
13.7%Antimalarial13.7%Hydroxychloroquine Sulfate100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Understanding disease modifying antirheumatic drug use in older adults with late-onset rheumatoid arthritis
University of Michigan at Ann Arbor
FY2026$194,400K23AG082727 - Understanding disease modifying antirheumatic drug use in older adults with late-onset rheumatoid arthritis
University of Michigan at Ann Arbor
FY2025$194,400K23AG082727 - Understanding disease modifying antirheumatic drug use in older adults with late-onset rheumatoid arthritis
University of Michigan at Ann Arbor
FY2024$194,400K23AG082727
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Serious infection risk in older adults with RA receiving biologic or targeted synthetic DMARDs: the role of age at disease onset
Therapeutic Advances in Musculoskeletal Disease
2026 - Clinician-Reported DMARD Disruption During Skilled Nursing Facility Transitions Among Older Adults With Rheumatic Diseases
Journal of the American Medical Directors Association
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”